pirbuterol ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
bronchodilators, phenethylamine derivatives 2199 38677-81-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • pirbuterol
  • (+/-)-Pirbuterol
  • pirbuterol acetate
  • pirbuterol hydrochloride
  • pirbuterol HCl
  • Molecular weight: 240.30
  • Formula: C12H20N2O3
  • CLOGP: -0.03
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 4
  • TPSA: 85.61
  • ALOGS: -1.59
  • ROTB: 5

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.20 mg Inhal.aerosol
30 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.14 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Dec. 30, 1986 FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R03AC08 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Selective beta-2-adrenoreceptor agonists
ATC R03CC07 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS FOR SYSTEMIC USE
Selective beta-2-adrenoreceptor agonists
FDA MoA N0000009922 Adrenergic beta2-Agonists
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D058666 Adrenergic beta-2 Receptor Agonists
MeSH PA D000318 Adrenergic beta-Agonists
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D001993 Bronchodilator Agents
MeSH PA D002316 Cardiotonic Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D020011 Protective Agents
MeSH PA D019141 Respiratory System Agents
FDA EPC N0000175779 beta2-Adrenergic Agonist

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Bronchiectasis indication 12295008 DOID:9563
Disorder of lung indication 19829001 DOID:850
Bronchitis indication 32398004 DOID:6132
Pulmonary emphysema indication 87433001
Asthma indication 195967001 DOID:2841
Asthma management indication 406162001
Acute exacerbation of asthma indication 708038006
Bronchospasm Prevention indication
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Hypokalemia contraindication 43339004
Conduction disorder of the heart contraindication 44808001
Diabetes mellitus contraindication 73211009 DOID:9351
Chronic myocardial ischemia contraindication 413844008 DOID:3393




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.36 acidic
pKa2 13.79 acidic
pKa3 9.38 Basic
pKa4 2.77 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-2 adrenergic receptor GPCR AGONIST WOMBAT-PK CHEMBL

External reference:

IDSource
4019898 VUID
N0000147983 NUI
D00686 KEGG_DRUG
65652-44-0 SECONDARY_CAS_RN
4019495 VANDF
4019898 VANDF
C0071129 UMLSCUI
CHEBI:8245 CHEBI
CHEMBL1094966 ChEMBL_ID
DB01291 DRUGBANK_ID
CHEMBL1200444 ChEMBL_ID
4845 PUBCHEM_CID
C009118 MESH_SUPPLEMENTAL_RECORD_UI
7272 IUPHAR_LIGAND_ID
3477 INN_ID
38029-10-6 SECONDARY_CAS_RN
OG645J8RVW UNII
221142 RXNORM
5307 MMSL
d00755 MMSL
001817 NDDF
001818 NDDF
001819 NDDF
108611006 SNOMEDCT_US
108612004 SNOMEDCT_US
372516006 SNOMEDCT_US
CHEMBL3989646 ChEMBL_ID
CHEMBL1997417 ChEMBL_ID

Pharmaceutical products:

None